Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BLKR201 in Healthy Adult Participants

NCT07501039 is registered in ClinicalTrials.gov with Formation Bio, Inc. as lead sponsor.

NCT NCT07501039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07501039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BLKR201 in Healthy Adult Participants
Lead sponsor
Formation Bio, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 27, 2026
Completion date
February 28, 2027
Enrollment
128 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy